Christoph Kasper

Christoph Kasper has been working in the field of biotechnology since 2008. Christoph began as a PhD student and Postdoctoral Fellow at the Biozentrum, University of Basel. In 2014, they became a Project Manager and PostDoc at Type 3 Technologies (Biozentrum, University of Basel). In 2015, they co-founded T3 Pharmaceuticals AG, where they currently serve as the Chief Scientific Officer. Their vision for the company is to improve the lives of cancer patients with highly innovative treatments.

Christoph Kasper began their educational journey in 1999 when they earned their Higher Education Entrance Qualification from Kantonsschule Olten in Mathematics and Natural Sciences. In 2003, they graduated from the University of Basel with a Bachelor of Science (B.Sc.) in Molecular Biology. Two years later, they obtained a Master of Science (M.Sc.) in Cell Biology/Infection Biology from the same university. Finally, in 2008, Kasper graduated from the Biozentrum, University of Basel with a Doctor of Philosophy (Ph.D.) in Infection Biology / Innate Immunity.